Cyrus Biotechnology Financing
Cyrus Biotechnology, Inc., Corporation just submitted form D because of $500,000 equity financing. This is a new filing. Cyrus Biotechnology was able to fundraise $490,000. That is 98.00% of the offering. The total offering amount was $500,000. The form was filed on 2016-11-16. The reason for the financing was: unspecified. The fundraising still has about $10,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Cyrus Biotechnology is based in Washington. The filler’s business is Biotechnology. The form D was signed by Lucas Nivon CEO. The company was incorporated in 2014. The filler’s address is: 500 Yale Avenue North, Seattle, Wa, Washington, 98109. Nivon Lucas is the related person in the form and it has address: 500 Yale Ave N, Seattle, Wa, Washington, 98109. Link to Cyrus Biotechnology Filing: 000164124116000003.
Analysis of Cyrus Biotechnology Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Cyrus Biotechnology sold 98.00% of the offering. The financing is still open. Could this mean that the trust in Cyrus Biotechnology is high? The average investment size for companies in the Biotechnology industry is $3.08 million. The offering was 84.09% smaller than the average of $3.08 million. Of course this should not be taken as negative. Companies raise funds for a variety of needs and reasons. The minimum investment for this financing was set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Cyrus Biotechnology Also
The Form D signed by Lucas Nivon might help Cyrus Biotechnology, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.